Table 1.
Associations between the expression of FGG and clinicopathological characteristics of 79 hepatocellular carcinoma patients
| Clinicopathological variables | FGG expression, IHC
|
Chi-squared value | P-value | |
|---|---|---|---|---|
| Weak (n=25) | Moderate/strong (n=54) | |||
|
| ||||
| Age (years) | ||||
| <55 | 11 | 25 | 0.036 | 0.849 |
| ≥55 | 14 | 29 | ||
| Gender | ||||
| Male | 24 | 51 | 0.086 | 1.000 |
| Female | 1 | 3 | ||
| Tumor size (cm) | ||||
| ≤5 | 16 | 22 | 2.546 | 0.111 |
| >5 | 9 | 32 | ||
| Satellite nodules | ||||
| Yes | 1 | 22 | 11.177 | 0.001** |
| No | 24 | 32 | ||
| Tumor encapsulation | ||||
| Absent | 15 | 24 | 1.654 | 0.198 |
| Present | 10 | 30 | ||
| Macrovascular invasion | ||||
| Yes | 0 | 12 | 6.551 | 0.014* |
| No | 25 | 42 | ||
| Microvascular invasion | ||||
| Yes | 6 | 33 | 9.416 | 0.002*** |
| No | 19 | 21 | ||
| AFP (ng/mL) | ||||
| <400 | 5 | 12 | 0.050 | 0.823 |
| ≥400 | 20 | 42 | ||
| HBV DNA (cps/mL) | ||||
| <500 | 14 | 21 | 2.028 | 0.154 |
| ≥500 | 11 | 33 | ||
| BCLC stage | ||||
| 0–A | 22 | 38 | 2.908 | 0.088 |
| B–D | 3 | 16 | ||
| TNM stage | ||||
| I | 21 | 22 | 12.893 | <0.001*** |
| II–IV | 4 | 32 | ||
| Fibrinogen levels (g/L) | ||||
| <4.0 | 18 | 46 | 1.931 | 0.219 |
| ≥4.0 | 7 | 8 | ||
Note:
*
P<0.05,
**
P<0.01,
***
P<0.001.
Abbreviations: AFP, a-fetoprotein; BCLC, Barcelona Clinic Liver Cancer staging; FGG, fibrinogen gamma chain; IHC, immunohistochemistry.